4 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 8 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 3, Completed 2, Terminated 2, Active not recruiting 1 |
| Phase 2 | 6 | Completed 3, Recruiting 2, Active not recruiting 1 |
Follow Microsatellite Stable Colorectal Cancer: new trials by email Literature Review of Microsatellite Stable Colorectal Cancer trials Research Report on Microsatellite Stable Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of VET3-TGI in Patients With Solid Tumors VET3-TGI, Atezolizumab - Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer | Phase 1 | Recruiting | KaliVir Immunotherapeutics | 60 | 2024-09-16 | 2026-04-07 |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors BMS-986340, BMS-936558-01, Docetaxel - Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 1109 | 2021-05-27 | 2026-08-17 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NT-I7, pembrolizumab (KEYTRUDA®) - Any Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | NeoImmuneTech | 215 | 2020-06-10 | 2026-03-09 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors TBio-6517, Pembrolizumab - Solid Tumor, Microsatellite Stable Colorectal Cancer | Phase 1 | Terminated | Turnstone Biologics, Corp. | 27 | 2020-06-02 | 2025-04-23 |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma GB1275, nab-paclitaxel and gemcitabine, pembrolizumab - Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma | Phase 1 | Terminated | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | 61 | 2019-08-13 | 2022-08-18 |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. DKY709, PDR001 - Carcinoma, Non-Small-Cell Lung, Melanoma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 98 | 2019-05-07 | 2026-10-19 |
| Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer grapiprant, grapiprant and pembrolizumab - Microsatellite Stable Colorectal Cancer | Phase 1 | Completed | Arrys Therapeutics | 54 | 2018-09-20 | 2023-10-24 |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Navarixin, Pembrolizumab - Solid Tumors, Non-small Cell Lung Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 107 | 2018-04-10 | 2024-08-28 |
| Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Nivolumab, Ipilimumab, Radiation Therapy - Microsatellite Stable Colorectal Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Massachusetts General Hospital | 84 | 2017-05-10 | 2026-06-12 |
| A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Ipilimumab, Nivolumab, Cobimetinib - Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 385 | 2014-03-12 | 2025-11-06 |
Carcinoma, Non-Small-Cell Lung (6) · Carcinoma, Renal Cell (4) · Melanoma (4) · Triple Negative Breast Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Mesothelioma (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma Of Esophagus (1) · Adenomatous Polyposis Coli (1)
Neoplasms by Site (9) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Bronchial Neoplasms (6) · Carcinoma (6) · Carcinoma, Bronchogenic (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Lung Diseases (6) · Lung Neoplasms (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6)
pembrolizumab (5) · Nivolumab (4) · Ipilimumab (2) · spartalizumab (2) · 130-nm albumin-bound paclitaxel (1) · 2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Docetaxel (1) · Fluorouracil (1) · Gemcitabine (1) · Leucovorin (1) · Oxaliplatin (1) · Radiotherapy (1) · atezolizumab (1)
Bristol-Myers Squibb (2) · Arrys Therapeutics (1) · GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. (1) · KaliVir Immunotherapeutics (1) · Massachusetts General Hospital (1) · Merck Sharp & Dohme LLC (1) · NeoImmuneTech (1) · Novartis Pharmaceuticals (1) · Parabilis Medicines, Inc. (1) · Turnstone Biologics, Corp. (1)
United States (11) · Australia (4) · Canada (4) · Spain (3) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · South Korea (2) · Belgium (1) · France (1) · Hong Kong (1) · Ireland (1) · Taiwan (1) · United Kingdom (1)
Benjamin Oshrine (1) · Ines Verdon, MD (1) · Julie Koenig, MD (1) · Sergio Santillana, MD (1)
PMID 28734759, PMID 29355075, PMID 34606846, PMID 34637336, PMID 35122060, PMID 38324085, PMID 38821718, PMID 39956770, PMID 40318595
2018 (1), 2023 (1)